Results 181 to 190 of about 10,654,926 (399)

The Middle Ages [7th grade World History] [PDF]

open access: yes, 2018
This four week unit is designed for middle school students. It analyzes the society, government, geography, culture, religion, and economy of the Middle Ages in Europe.
JENSEN, KATELYN
core   +1 more source

Clinical significance of stratifying prostate cancer patients through specific circulating genes

open access: yesMolecular Oncology, EarlyView.
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian   +12 more
wiley   +1 more source

The translation in the middle ages [PDF]

open access: yes, 2015
In the Middle Ages the main attention was paid to the translations in the field of mathematics, medicine, astronomy, astrology, because Europe remains relatively poor in its scientific achievements.
Kovalyova, E.M.   +3 more
core  

Etoposide‐induced cancer cell death: roles of mitochondrial VDAC1 and calpain, and resistance mechanisms

open access: yesMolecular Oncology, EarlyView.
The complex mode of action of the topoisomerase II inhibitor etoposide in triggering apoptosis involves several mechanisms: overexpression of the mitochondrial protein VDAC1, leading to its oligomerization and formation of a large channel that mediates the release of pro‐apoptotic protein; and overexpression of the apoptosis regulators p53, Bax, and ...
Aditya Karunanithi Nivedita   +1 more
wiley   +1 more source

Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis

open access: yesAging and Cancer, Volume 3, Issue 3-4, Page 133-146, September-December 2022., 2022
One‐third of DLBCL arises from extranodal organs and is challenging to manage. Molecular features are critical to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and ...
Si‐Yuan Chen   +3 more
wiley   +1 more source

Sarcenic Civilization in the Middle Ages [PDF]

open access: yes, 1926
Of all the older nations who have carried their arms across vast continents,whose fleets have swept the seven seas, and who have left ineffaceable marks of their achievements on the pages of History, and enriched the world of thought by their discoveries
Ahern, Helene M.
core   +1 more source

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

open access: yesMolecular Oncology, EarlyView.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric   +11 more
wiley   +1 more source

Vibrational Spectroscopic Analyses and Imaging of the Early Middle Ages Hemp Bast Fibres Recovered from Lake Sediments. [PDF]

open access: yesMolecules, 2021
Kalisz G   +5 more
europepmc   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

open access: yesMolecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy